Jafari A, Panahi N, Hesaraki S, Akbari G
Department of Veterinary Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Department of Veterinary Pathobiology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Arch Razi Inst. 2024 Oct 31;79(5):1065-1074. doi: 10.32592/ARI.2024.79.5.1065. eCollection 2024 Oct.
Quercetin (Qu) is a type of plant flavonoid that has been demonstrated to possess anti-proliferative properties, making it a potentially beneficial agent in the treatment of prostate hyperplasia. Additionally, Nigella sativa seed oil (NSO) has demonstrated efficacy in alleviating symptoms associated with benign prostatic hyperplasia (BPH). The objective of this study is to evaluate the impact of quercetin (Qu) in combination with a nanoemulsion derived from Nigella sativa seed oil (Qu-NSO) on a rat model of benign prostatic hyperplasia (BPH). The study employed a rat model of BPH, whereby testosterone enanthate (5 mg/kg) was administered subcutaneously to induce the condition. The rats were then treated with various interventions, including Qu (25 mg/kg and 50 mg/kg), NSO, and Qu-NSO (25 mg/kg and 50 mg/kg), with a total volume of 0.5 ml administered orally. This allowed for an assessment of the effects of Qu-NSO. The self-nanoemulsified drug delivery system was prepared using NSO, coconut oil, Tween 80, and polyethylene glycol 400 (PEG). The globule size and zeta potential of the formed vesicles were determined. Investigations were conducted on the rat model to examine the effects of the treatments on dihydrotestosterone (DHT), prostate-specific antigen (PSA), prostatic weight and index, oxidant and antioxidant markers, and histopathology. The mean globule size for Qu-NSO was 171.9±10.9 nm, with a zeta potential value of +17.3 mV. The Qu-NSO treatment resulted in a 40% reduction in prostate weight and an 86.71% reduction in prostate index compared to the testosterone-treated group. The Qu-NSO treatment resulted in a significant reduction in serum levels of oxidative contents (MDA) (p<0.0001), while antioxidative substances (SOD and GPx activity) exhibited a significant increase (p<0.0001). The Qu-NSO group exhibited superior outcomes in terms of decreasing prostatic weight and enhancing antioxidative properties, as evidenced by elevated antioxidant enzyme activity. This study demonstrated that the Qu and NSO in a Qu NSO formula augmented the Qu efficacy in managing BPH. Quercetin (Qu) is a type of plant flavonoid that is beneficial in fighting prostate hyperplasia cells. Meanwhile, seed oil (NSO) has shown promise in relieving benign prostatic hyperplasia (BPH) symptoms. This study aims to assess the effects of Qu combined with NSO-based nanoemulsion (Qu-NSO) against a rat model of BPH. The study involved the induction of BPH in rats using testosterone enanthate (5 mg/kg) subcutaneously and administering different treatments, including Qu (25 mg/kg and 50 mg/kg), NSO, and Qu-NSO (25 mg/kg and 50 mg/kg), with total volume 0.5 ml per oral to assess the effects of Qu-NSO. NSO, coconut oil, Tween 80, and polyethylene glycol 400 (PEG) were obtained for the self-nano-emulsified drug delivery system. The globule size and zeta potential of formed vesicles were measured. Dihydrotestosterone (DHT), prostate-specific antigen (PSA), prostatic weight and index, oxidant and antioxidant markers, and histopathology were investigated in the rat model. The average globule size for Qu-NSO was 171.9±10.9 nm, with a zeta potential value of +17.3 mV. Qu-NSO declined prostate weight by 40% and prostate index by 86.71% compared to the testosterone group. Qu-NSO treatment significantly reduced the serum levels of oxidative contents (MDA) (<0.0001), while antioxidative substances (SOD and GPx activity) were significantly more (<0.0001). Qu-NSO was superior to the finasteride group in decreasing prostatic weight and antioxidative properties, such as increasing antioxidant enzyme activity. This study revealed that the Qu and NSO in a Qu NSO formula enhanced the Qu efficacy in managing BPH..
槲皮素(Qu)是一种植物类黄酮,已被证明具有抗增殖特性,使其成为治疗前列腺增生的潜在有益药物。此外,黑种草籽油(NSO)已证明在缓解良性前列腺增生(BPH)相关症状方面具有疗效。本研究的目的是评估槲皮素(Qu)与源自黑种草籽油的纳米乳剂(Qu-NSO)联合使用对良性前列腺增生(BPH)大鼠模型的影响。该研究采用了BPH大鼠模型,通过皮下注射庚酸睾酮(5mg/kg)来诱导该病症。然后,给大鼠进行各种干预治疗,包括Qu(25mg/kg和50mg/kg)、NSO以及Qu-NSO(25mg/kg和50mg/kg),口服给药总体积为0.5ml。这使得能够评估Qu-NSO的效果。使用NSO、椰子油、吐温80和聚乙二醇400(PEG)制备了自纳米乳化药物递送系统。测定了形成的囊泡的球粒大小和zeta电位。对大鼠模型进行研究,以检查这些治疗对二氢睾酮(DHT)、前列腺特异性抗原(PSA)、前列腺重量和指数、氧化和抗氧化标志物以及组织病理学的影响。Qu-NSO的平均球粒大小为171.9±10.9nm,zeta电位值为+17.3mV。与睾酮治疗组相比,Qu-NSO治疗使前列腺重量降低了40%,前列腺指数降低了86.71%。Qu-NSO治疗使血清氧化成分(MDA)水平显著降低(p<0.0001),而抗氧化物质(SOD和GPx活性)则显著增加(p<0.0001)。Qu-NSO组在减轻前列腺重量和增强抗氧化特性方面表现出更好的效果,抗氧化酶活性升高证明了这一点。本研究表明,Qu NSO配方中的Qu和NSO增强了Qu在管理BPH方面的疗效。槲皮素(Qu)是一种对对抗前列腺增生细胞有益的植物类黄酮。同时,黑种草籽油(NSO)在缓解良性前列腺增生(BPH)症状方面显示出前景。本研究旨在评估Qu与基于NSO的纳米乳剂(Qu-NSO)联合使用对BPH大鼠模型的影响。该研究涉及通过皮下注射庚酸睾酮(5mg/kg)在大鼠中诱导BPH,并给予不同治疗,包括Qu(25mg/kg和50mg/kg)、NSO以及Qu-NSO(25mg/kg和50mg/kg),每次口服总体积为0.5ml以评估Qu-NSO的效果。获取NSO、椰子油、吐温80和聚乙二醇400(PEG)用于自纳米乳化药物递送系统。测量了形成的囊泡的球粒大小和zeta电位。在大鼠模型中研究了二氢睾酮(DHT)、前列腺特异性抗原(PSA)、前列腺重量和指数、氧化和抗氧化标志物以及组织病理学。Qu-NSO的平均球粒大小为171.9±10.9nm,zeta电位值为+17.3mV。与睾酮组相比,Qu-NSO使前列腺重量下降了40%,前列腺指数下降了86.71%。Qu-NSO治疗显著降低了血清氧化成分(MDA)水平(<0.0001),而抗氧化物质(SOD和GPx活性)则显著增加(<0.0001)。在减轻前列腺重量和抗氧化特性方面,如增加抗氧化酶活性方面,Qu-NSO优于非那雄胺组。本研究揭示了Qu NSO配方中的Qu和NSO增强了Qu在管理BPH方面的疗效。